GlaxoSmithKline Hold
FRANKFURT (dpa-AFX Analyser) - Die Deutsche Bank hat GlaxoSmithKline (GSK)mit "Hold" und einem Kursziel von 1400 Pence in die Bewertung…
Börse:
15,865€
0,03%
Echtzeit-Aktienkurs GLAXOSMITHKLINE LS-,25
Bid:
15,860€
Ask:
15,870€
Nachrichten zur GLAXOSMITHKLINE LS-,25 Aktie
GlaxoSmithKline Neutral
NEW YORK (dpa-AFX Analyser) - Die JPMorgan hat die Einstufung für GlaxoSmithKline nach der Healthcare Conference der US-Bank auf "Neutral"…
Director Deals - Glaxosmithkline PLC (GSK)
Um den gesamten Artikel unter stockmarketwire.com zu lesen, klicken Sie bitte auf die Überschrift...…
Vir Biotech, Glaxo to Begin Study on Second COVID-19 Therapy
Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate....…
GSK, Vir Biotechnology to evaluate neutralising Covid-19 antibody in AGILE study
VIR-7832, a neutralising Covid-19 antibody, attaches to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1. According to GSK, the…
British drug giants ramp up battle against Covid-19 with a race for vaccine approvals
On a day of major developments, Glaxosmithkline said it was joining an NHS study to test a breakthrough antibody treatment.…
Glaxo Aims to Double Blockbusters in Bid to Revive Portfolio
Glaxo Aims to Double Blockbusters in Bid to Revive Portfolio...…
Vir Bio, GSK ink deal with AGILE to evaluate VIR-7832 in COVID-19
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
TOP NEWS: GSK, Vir To Probe Second Virus Antibody In NHS-Backed Trial
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
SAN FRANCISCO and LONDON, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc…
Glaxo, Eligo Bioscience in $224M deal for eligobiotics based therapies
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Eligo inks deal with GSK potentially worth up to $224M
PARIS , Jan. 11, 2021 /PRNewswire/ -- Eligo Bioscience SA (Eligo) today announced that…
GSK, MMV filing for Kozenis in paediatric populations with P. vivax malaria accepted by Australian TGA
The application includes data for a new, 50 mg tablet that can be dispersed in water and which was developed…
The Zacks Analyst Blog Highlights: UnitedHealth Group, Netflix, Caterpillar, General Electric and GlaxoSmithKline
The Zacks Analyst Blog Highlights: UnitedHealth Group, Netflix, Caterpillar, General Electric and GlaxoSmithKline...…
Biotech-Überflieger Zai Lab: Mit GlaxoSmithKline, Incyte und Co hoch hinaus – AKTIONÄR-Tipp 360% im Plus
Die Biotech-Gesellschaft Zai Lab ist einer der chinesischen Überflieger an der Tech-Börse Nasdaq. Mittlerweile beträgt die Marktkapitalisierung gut zwölf Milliarden…
Goldseek Completes its Extended (1,800m) Drill Program at Bonanza (Urban Barry)
January 7th, 2021 – TheNewswire - London, Ontario – Goldseek Resources Inc. (CSE:GSK) (CNSX:GSK.CN) (“Goldseek” or the “Company”) is pleased…
GlaxoSmithKline (GSK) Presents At Morgan Stanley ESG Conference 2020 - Slideshow
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
GlaxoSmithKline buy
NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat die Einstufung für GlaxoSmithKline auf "Buy" mit einem Kursziel von…
GlaxoSmithKline Neutral
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat GlaxoSmithKline (GSK) auf "Neutral" mit einem Kursziel von 1500 Pence belassen.…
Pfizer, GSK & Others Quietly Hike Prices On 100s Of Drugs
Pfizer, GSK & Others Quietly Hike Prices On 100s Of Drugs
…
Exclusive: Drugmakers to hike prices for 2021 as pandemic, political pressure put revenues at risk
Drugmakers including Pfizer Inc, Sanofi SA, and GlaxoSmithKline Plc plan to raise U.S. prices on more than 300 drugs in…
Vectura Says Glaxo Will Not Appeal Award In Ellipta Litigation
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
The Zacks Analyst Blog Highlights: AMZN, WMT, UNH, MS and GSK
The Zacks Analyst Blog Highlights: AMZN, WMT, UNH, MS and GSK...…
Drug giants to be at heart of post-Brexit UK
GSKs HIV drug Vocabria has been given the green light in Europe. At the same time, rival Astrazeneca said…
Glaxo and Astrazeneca get green lights for HIV and lung cancer drugs
Glaxosmithklines long-acting HIV drug Vocabria - which reduces the number of times patients need to medicate from 365 days a…
GSK bags rights to Sosei Heptares drugs against digestive disorder target
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
TOP NEWS: Glaxo Receives EU Marketing Authorisation For HIV Treatment
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
GlaxoSmithKline says EU approves HIV treatment
GlaxoSmithKline PLC said Monday that the EU has granted marketing authorization for ViiV Healthcare's long-acting HIV treatment Vocabria. The British…
GlaxoSmithKline-owned ViiV Healthcare receives green light for long-acting HIV treatment
ViiV Healthcare, the specialist HIV company majority-owned by GlaxoSmithKline PLC (LON:GSK), has received marketing approval for a long-acting therapy for…
GlaxoSmithKline PLC-owned ViiV Healthcare receives green light for long-acting HIV treatment
ViiV Healthcare, the specialist HIV company majority-owned by GlaxoSmithKline PLC (LON:GSK), has received marketing approval for a long-acting therapy for…
Sosei Heptares and GSK Enter Global Collaboration and License Agreement Targeting Immune Disorders of the Digestive System
TOKYO and CAMBRIDGE, England , Dec. 21, 2020 /PRNewswire/ -- Sosei Group Corporation…
GSK is closing in on two major drug deals: Report
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
GlaxoSmithKline gets booster from £100m drug deals spree
They come on top of two link-ups - one to license Bostons Surface Oncologys early-stage cancer drugs - and another…
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
In the latest trading session, GlaxoSmithKline (GSK) closed at $37.01, marking a -0.88% move from the previous day....…
Vir, GSKs experimental COVID-19 treatment moves into a Phase 3 clinical trial
Shares of Vir Biotechnology Inc. gained 1.3% in premarket trading on Friday, the day after the biotech and GlaxoSmithKline…
GSK gets FDA nod for Benlysta to treat adult patients with active lupus nephritis
Lupus nephritis, an inflammation of the kidneys caused by systemic lupus erythematosus (SLE), may lead to end-stage kidney disease. Benlysta,…
GlaxoSmithKline And Vir Biotechnology Kick Off ACTIV-3 Covid Trial
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
Vir Biotechnology and GSK Announce Start of NIH-Sponsored ACTIV-3 Trial Evaluating VIR-7831 in Hospitalized Adults with COVID-19
– Randomized, placebo-controlled, multicenter, global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalized adults with…
Surface Oncology shares rise 7% on licensing deal with GSK for immunotherapy program
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Surface Oncology Announces Exclusive License Agreement with GSK for Novel Immunotherapy Program
GSK will have exclusive rights to develop and commercialize SRF813, a novel antibody targeting PVRIG...…
GlaxoSmithKline kaufen
FRANKFURT (dpa-AFX Analyser) - Die DZ Bank hat den fairen Wert für GlaxoSmithKline von 1750 auf 1700 Pence gesenkt, aber…
GlaxoSmithKline Neutral
ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat die Einstufung für GlaxoSmithKline (GSK) nach einem Rückschlag bei der Corona-Impfstoffentwicklung…
Glaxo Bids $120 a Share for Eidos in Rival Offer
Glaxo Bids $120 a Share for Eidos in Rival Offer...…
Impfstoff von Sanofi und GSK verzögert sich
Börsen-Zeitung, 12.12.2020 wü Paris - Der französische Pharmariese Sanofi und sein britischer Partner GlaxoSmithKline (GSK) haben gewarnt, dass es bei…
Sanofi and GlaxoSmithKline Delay COVID-19 Vaccine Program Due to Poor Immune Response in Older Adults
The vaccine giants will be rethinking the formulation of their coronavirus candidate before a new phase 2 study....…
Glaxo (GSK)/Sanofi Delay Study on Coronavirus Vaccine Candidate
Glaxo (GSK)/Sanofis (SNY) adjuvanted recombinant COVID-19 vaccine candidate shows low immune response in older adults in phase I/II study. The…
Sanofi and Glaxo Delay Their Covid Vaccine
As the field separates in the vaccine race, the opportunity for sales and pricing power looks better for front-runners Pfizer…
Corona-Impfstoff: Sanofi und Glaxosmithkline müssen Studie wiederholen
Die beiden größten Impfstoffproduzenten der Welt enttäuschen mit ihrem Corona-Vakzin. Sanofi und Glaxosmithkline müssen ihre klinische Studie wiederholen, weil die…
The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street
Heres a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week…
GSK/Sanofi Covid vaccine delayed until end of next year
Trials reveal vaccine failed to produce a strong immune response in older peopleCoronavirus – latest updatesSee all our coronavirus coverageA…